Dr Timothy Cooke | Chief Executive Officer
NovaDigm Therapeutics

Dr Timothy Cooke, Chief Executive Officer, NovaDigm Therapeutics

Dr. Cooke joined NovaDigm Therapeutics as Chief Executive Officer in 2009. He has broad leadership experience in both emerging and large multinational companies in the fields of vaccines and immunotherapeutics. Dr. Cooke joined Merck when it launched a dedicated vaccine business unit in 1991 and was also a founding member of Sanofi Pasteur-MSD, a European joint venture between Sanofi Pasteur and Merck. Dr. Cooke was the Chief Executive Officer of Mojave Therapeutics, a company developing therapeutic vaccines against viral infections and cancer, which was sold to Antigenics in 2004. He was then Chief Operating Officer of AVANT Immunotherapeutics prior to its acquisition by CellDex Therapeutics in 2008. 
Dr. Cooke is a member of the National Vaccine Advisory Committee of the U.S. Department of Health and Human Services, where he represents the biotechnology industry.  He is a member and previous Co-Chair of the Biotechnology Innovation Organization’s Vaccine Policy Advisory Committee and a member of BIO’s Antimicrobial Resistance Working Group.  He represented the vaccine industry on the Global Alliance for Vaccines and Immunization (GAVI) Working Group when it was launched in 2000.  Dr. Cooke has a bachelor’s degree from Saint Joseph’s University, and a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University.


April 14 Pre-congress Workshop Day @ 10:00


Anti-Infective ImmunotherapiesShould there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically? Join this workshop to understand how anti-infective immunotherapies are increasingly combined and the role of both passive and active immunization in future.
  • Scientific rationale & landscape of antibodies in preclinical and clinical development for infectious diseases
  • Anti-fungal Immunotherapy – Candida vaccine
  • ​​Anti-fungal immunotherapy – Cryptococcus Neoformans vaccine
  • RSV and bacterial (Sa and Pa) prophylactic monoclonals in development
  • Development and testing of a human IgG1 monoclonal antibody to the broadly conserved microbial surface polysaccharide, PNAG
  • ​​​​​​​Bacterial mAbs and vaccine approaches
  • MAbs against viruses
  • Designing and Engineering antibodies to mutable protein targets
  • Regulatory Strategy and guidance on developing anti-infective immunotherapies​​​​​​​
last published: 21/Mar/19 15:25 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071